A combination of Sacubitril, a neprilysin inhibitor, and Valsartan, an ARB. Marketed as an angiotensin receptor-neprilysin inhibitor (ARNI), it is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril increases natriuretic peptides, promoting vasodilation and sodium excretion, while Valsartan blocks angiotensin II effects.
Reviews
There are no reviews yet.